Replies to post #22503 on RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

RD was where Greer had his animal data, and was thus the first logical choice. Having achieved that, SA is a natural next step--but they need regulatory approval for CX717 testing in a new indication, either in the US or Europe, and the money to run a trial. Also: sleep investigators would not have been inclined to try CX717 in SA without the RD data.

NeuroInvestment

[gfp927z]

Cortex's cash level now under $4 mil.